

- components of lepra cells. *Int. J. Lepr.* **28** (1960) 22–37.
8. KHANOLKAR, V. R. Pathology of leprosy. In: *Leprosy in Theory and Practice*. 2nd ed. Cochrane, R. G. and Davey, T. E., eds. Bristol: John Wright & Sons Limited, 1964, pp. 125–151.
 9. MITSUDA, K. The significance of the vacuole in Virchow lepra cells and the distribution of lepra cells in certain organs. *Tokyo J. Med. Affairs* **2066** (1918) 1–7. English translation in *Int. J. Lepr.* **4** (1936) 491–507.
 10. SAKURAI, I. and SKINSNES, O. K. Lipids in leprosy. 2. Histochemistry of lipids in human leprosy. *Int. J. Lepr.* **38** (1970) 389–403.
 11. SUFAI, K. Histopathological studies on human leprosy. IV. Histochemical analysis of abnormal fats in lepromatous leprosy especially on fat deposition in lymph nodes. *Lepro* **27** (1958) 216–227.
 12. YAMAMOTO, T., NISHIURA, M., HARADA, N. and IMAEDA, T. Electron microscopy of ultra-thin sections of lepra cells and *M. leprae*. *Int. J. Lepr.* **26** (1958) 1–8.

Co-incident (Simultaneous) Dapsone Sensitivity and Dapsone-resistant Leprosy

TO THE EDITOR:

It was interesting to read the letter of Dr. McDougall and Dr. Felton Ross [IJL **50** (1982) 214–215] concerning co-incident (simultaneous) dapsone sensitivity and dapsone-resistant leprosy. They ask whether leprosy workers in other parts of the world have observed findings similar to theirs.

This occurrence was first proved by workers from the British Medical Research Council's unit in Sungei Buloh, Malaysia, in the initial series of papers which proved the existence of sulfone-resistant leprosy.

Our Indian patient No. 5075 was No. 1 in the first seven cases we studied for resistance⁽²⁾ and also No. 1 in the more detailed report printed in 1966⁽³⁾. Although the sensitivity tests that were first performed found him to have a strain of dapsone-sensitive organisms, his Morphological Index did not diminish as much as might have been expected after six months on injectible DDS (600 mg weekly).

This case was reported in much greater detail in 1968 as "A Case of 'Partial' Resistance"⁽¹⁾ which describes how his Morphological Index fluctuated wildly while on sulfone treatment. In March 1963 the biopsies (we always took two from different sites) showed definite active lepromas and he was treated with 300 mg of dapsone twice weekly. About eight months later further biopsies seemed quiescent although Dr. Ridley not-

ed "one more than the other." In April 1964 however the biopsies again showed definitely active leprosy. In the next eight months he had a severe bout of erythema nodosum leprosum which we believe is associated with successful anti-mycobacterial therapy, yet by February 1965 the biopsies still showed definite evidence of activity. At that time he was put on clofazimine therapy and from then on got steadily better by all criteria—clinical, bacteriological, and pathological.

We were treating a patient whose initial lesions showed dapsone sensitivity but who improved and then got worse while under treatment—the skin plaques got smaller but a diffuse skin infiltration appeared.

In those early days we were not yet able to recognize the clinical appearance of sulfone-resistant leprosy, but in retrospect it is obvious that this patient had some lesions containing resistant organisms and others with sensitive organisms. We said in our summary that it was likely that more cases of this type will be found. Apparently this is now the case.

We must therefore accept that resistant leprosy may be due to two things:

1) The development of a resistant clone in a patient most of whose bacilli are sulfone-sensitive. It is a moot point whether this clone develops because of inadequate therapy or whether it was always there and

only revealed when the sensitive population disappeared.

2) Any lepromatous patient under satisfactory sulfone treatment is liable to catch a resistant form of leprosy, particularly if such immunologically susceptible individuals are living in a place where other cases with resistant organisms are likely to be found.

Some time ago I was asked to write an article for the "house paper" of a famous leprosarium and I wrote to the effect that leprosarria should be closed down—it was not published. It seems to me to be the height of stupidity to send lepromatous patients for admission to a hospital where, almost by definition, they are likely to meet sulfone-resistant mycobacteria. If this continues (to repeat our warning of 15 years ago),

it is likely that more cases of this type will be found.

—John H. S. Pettit, M.D., F.R.C.P.
Room 303
China Insurance Building
174 Jalan Tuanku Abdul Rahman
Kuala Lumpur, Malaysia

REFERENCES

1. PEARSON, J. M. H., PETTIT, J. H. S. and REES, R. J. W. Studies in sulfone resistance in leprosy. 3. A case of "partial" resistance. *Int. J. Lepr.* **36** (1968) 171–178.
2. PETTIT, J. H. S. and REES, R. J. W. Sulphone resistance in leprosy. An experimental and clinical study. *Lancet* **2** (1964) 673–674.
3. PETTIT, J. H. S., REES, R. J. W. and RIDLEY, D. S. Studies in sulfone resistance in leprosy. 1. Detection of cases. *Int. J. Lepr.* **34** (1966) 375–390.

Serum Levels of C3-activator (Antifactor B) in Leprosy

TO THE EDITOR:

There have been previous reports that during the eruption of crops of erythema nodosum leprosum (ENL) raised C2 and C3 levels in the sera of patients have been observed (6, 7). These two components are involved in the classical immune complex pathway of complement activation.

C3-activator (Antifactor B) is involved in the alternative pathway activation of complement (1), and recently *Mycobacterium leprae* bacilli have been shown to activate the alternative pathway of complement (3). It was considered pertinent to determine how the value of C3-activator varies in the leprosy sera, particularly during ENL when initially immune complexes and *M. leprae* bacilli could activate both paths of complement separately.

Sera were collected from 9 ENL, 3 non-ENL and 1 borderline patients from Japan and Addis Ababa, Ethiopia. The concentrations of C3-activator, the third component of complement (C3c) and immunoglobulins (IgG, IgA and IgM) in the patients' sera were determined by the radial im-

munodiffusion method of Mancini, *et al.* (2), using the standard immunoglobulin sera and the Partigen® immunodiffusion plates manufactured by Behringwerke AG (Marburg-Lahn) of West Germany.

Measured 5 µl volumes of the standards of IgG, IgA, IgM, C3c, and C3-activator were introduced into the first three wells and the same volume of test sera introduced into the remaining nine wells of each plate. The 13 mg/ml protein standard plasma used for C3-activator determination was used neat, diluted 1:2 and diluted 1:4 for the three standard wells. All the plates were allowed to stand at room temperature for 48–72 hr before the diameters of precipitin rings which developed around the wells were measured, using a Behringwerke precision measuring viewer. Graphs were plotted of ring diameters against the logarithm of the standard concentration, and the concentrations in the samples were determined from the plots. The results are given in The Table.

Moderate increases in the serum levels of C3-activator were observed only in ENL cases. The lowest values were observed in